Is Valneva (EPA:VLA) Using Too Much Debt?
Sep 10
Have your own idea? Try our Stock Screener
French (CAC) Biotech Industry Analysis
UpdatedSep 30, 2025
DataAggregated Company Financials
Companies22
- 7D-2.7%
- 3M29.9%
- 1Y2.5%
- YTD16.7%
Over the last 7 days, the Biotech industry has dropped 2.7%, driven by a pullback from Cellectis of 28%. Meanwhile, Nanobiotix actually outperformed within the industry, gaining 27% in the last week. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are expected to grow by 35% per annum.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 30 Sep 2025 | €2.3b | €643.4m | -€455,303,328.03 | 16x | -5x | 3.6x |
| Thu, 28 Aug 2025 | €2.3b | €674.3m | -€446,385,472.96 | 15.1x | -5.3x | 3.5x |
| Sat, 26 Jul 2025 | €2.2b | €655.5m | -€451,422,772.75 | 15.2x | -4.8x | 3.3x |
| Mon, 23 Jun 2025 | €1.9b | €666.6m | -€496,176,815.36 | 17.4x | -3.9x | 2.9x |
| Wed, 21 May 2025 | €2.4b | €673.8m | -€676,379,661.97 | 16.2x | -3.5x | 3.5x |
| Fri, 18 Apr 2025 | €2.2b | €650.8m | -€551,302,382.12 | 13.8x | -3.9x | 3.3x |
| Sun, 16 Mar 2025 | €2.3b | €664.3m | -€478,938,745.38 | 16.6x | -4.8x | 3.4x |
| Tue, 11 Feb 2025 | €2.5b | €650.6m | -€528,450,438.15 | 16.5x | -4.7x | 3.8x |
| Thu, 09 Jan 2025 | €2.4b | €650.5m | -€528,206,498.11 | 18.3x | -4.5x | 3.7x |
| Sat, 07 Dec 2024 | €2.4b | €654.1m | -€547,464,910.14 | 17.8x | -4.4x | 3.7x |
| Mon, 04 Nov 2024 | €2.8b | €640.1m | -€520,393,708.60 | 18.4x | -5.4x | 4.4x |
| Wed, 02 Oct 2024 | €2.8b | €641.0m | -€509,824,728.48 | 18.8x | -5.5x | 4.3x |
| Fri, 30 Aug 2024 | €3.2b | €520.5m | -€580,313,911.09 | 36.9x | -5.4x | 6.1x |
| Sun, 28 Jul 2024 | €2.9b | €511.7m | -€566,628,871.32 | 28.6x | -5.2x | 5.7x |
| Tue, 25 Jun 2024 | €3.0b | €514.3m | -€569,149,168.15 | 26.4x | -5.2x | 5.8x |
| Thu, 23 May 2024 | €3.4b | €502.5m | -€593,420,880.71 | 28.5x | -5.8x | 6.8x |
| Sat, 20 Apr 2024 | €3.2b | €515.7m | -€629,383,997.10 | 27.2x | -5.1x | 6.2x |
| Mon, 18 Mar 2024 | €3.1b | €567.8m | -€645,920,503.60 | 21.2x | -4.8x | 5.5x |
| Wed, 14 Feb 2024 | €3.0b | €559.1m | -€676,043,084.11 | 22.2x | -4.4x | 5.3x |
| Fri, 12 Jan 2024 | €3.1b | €594.2m | -€682,899,313.00 | 23.4x | -4.5x | 5.2x |
| Sun, 10 Dec 2023 | €3.2b | €594.8m | -€686,001,867.00 | 21.8x | -4.7x | 5.4x |
| Tue, 07 Nov 2023 | €3.3b | €803.4m | -€565,583,221.00 | 21.4x | -5.8x | 4.1x |
| Thu, 05 Oct 2023 | €3.3b | €831.4m | -€577,038,718.00 | 14.4x | -5.7x | 4x |
| Sat, 02 Sep 2023 | €3.9b | €818.3m | -€727,522,812.00 | 25.2x | -5.3x | 4.7x |
| Mon, 31 Jul 2023 | €3.8b | €817.6m | -€735,190,518.00 | 24.7x | -5.2x | 4.6x |
| Wed, 28 Jun 2023 | €3.8b | €819.7m | -€743,089,722.00 | 25.3x | -5.1x | 4.6x |
| Fri, 26 May 2023 | €3.7b | €826.4m | -€769,320,253.00 | 25.4x | -4.8x | 4.5x |
| Sun, 23 Apr 2023 | €3.5b | €877.9m | -€752,481,502.00 | 31.8x | -4.6x | 4x |
| Tue, 21 Mar 2023 | €3.2b | €1.0b | -€479,834,713.00 | 9.3x | -6.7x | 3.1x |
| Thu, 16 Feb 2023 | €3.7b | €1.0b | -€457,224,103.00 | 11.4x | -8x | 3.5x |
| Sat, 14 Jan 2023 | €3.8b | €1.0b | -€456,151,007.00 | 12.8x | -8.4x | 3.7x |
| Mon, 12 Dec 2022 | €3.5b | €1.0b | -€457,611,814.00 | 12.7x | -7.6x | 3.3x |
| Wed, 09 Nov 2022 | €3.5b | €905.0m | -€705,047,268.00 | 16.3x | -5x | 3.9x |
| Fri, 07 Oct 2022 | €3.6b | €923.6m | -€734,599,949.00 | 30.2x | -4.9x | 3.9x |
Price to Earnings Ratio
-4.9x
Current Industry PE
- Investors are pessimistic on the French Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 11% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | 0.83% | |
| Healthcare | -1.46% | |
| Biotech | -2.65% | |
| Biotech | -2.65% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NANO Nanobiotix | €14.10 | 26.6% +€142.7m | 183.7% | PE-10x | |
| ABVX ABIVAX Société Anonyme | €70.90 | 2.2% +€113.4m | 597.8% | PS889.6x | |
| IVA Inventiva | €4.94 | 5.8% +€37.6m | 193.0% | PS40.5x | |
| VLA Valneva | €4.57 | 4.7% +€35.4m | 71.8% | PS4x | |
| IPH Innate Pharma | €1.64 | 3.5% +€5.2m | -19.0% | PS11.9x |
